New challenges to the therapy of systemic fungal infections.
In summary, the recent increase in frequency of systemic fungal infections has stimulated the development of new antifungal agents which are easier to use and which have decreased toxicity. This has resulted in increase in use, and along with this, the appearance of fungi resistant to antifungal agents. The medical community will have to come to terms with this newly emerging problem.
Medoff
G
G
Infectious Diseases Division, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
D000666:Amphotericin B / Q000494:pharmacology; D000935:Antifungal Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy; D004352:Drug Resistance, Microbial; D015725:Fluconazole / Q000494:pharmacology; D006801:Humans; D009181:Mycoses / Q000188:drug therapy*; D013261:Sterols / Q000737:chemistry / Q000378:metabolism
D000935:Antifungal Agents; D013261:Sterols; D000666:Amphotericin B; D015725:Fluconazole